Abstract:Objective To investigate the value of neutrophil-lymphocyte ratio (NLR) combined with monocyte-lymphocyte ratio (MLR) in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) treated with artificial liver. Methods A retrospective analysis was performed for the clinical data of 81 who received artificial liver therapy for the first time from January 2016 to June 2019 in National Hospital of Guangxi Zhuang Autonomous Region, according to the prognosis at 90 days after the first artificial liver treatment, and these patients were divided into survival group with 63 patients and death group with 18 patients. Multivariate logistic regression was used to analyze the association of related factors with the prognosis of HBV-ACLF patients treated with artificial liver. The area under the ROC curve (AUC) of NLR combined with MLR was used to evaluate the value of NLR combined with MLR in predicting the short-term prognosis of HBV-ACLF patients treated with artificial liver. Results Compared with the survival group, the death group had significantly higher TBIL, creatinine, INR, MELD scores, NLR, MLR and CRP and a significantly lower prothrombin time activity (PTA) (P?0.05). Results of multivariate Logistic regression analysis showed that NLR (OlR?=?3.719, 95% CI: 3.525, 3.942) and MLR (OlR?=?2.335, 95% CI: 2.161, 2.596) were risk factors for the short-term prognosis of HBV-ACLF patients treated with artificial liver, while PTA (OlR?=?0.729, 95% CI: 0.550, 0.967) was a protective factor. The AUC of the combination of NLR and MLR which was 0.921 (95% CI: 0.876, 0.966) was the largest. The combined detection of NLR and MLR could improve the sensitivity [76.0% (95% CI: 0.723, 0.806)] and specificity [92.0% (95% CI: 0.882, 0.957)] of predicting the short-term prognosis of HBV-ACLF patients treated with artificial liver. Conclusion PTA and systemic inflammation indicators (NLR and MLR) are closely related to short-term prognosis of HBV-ACLF patients treated with artificial liver.